NAPLEX 2024 Test Bank: A Comprehensive Q&A
Study Guide with 100% Verified Answers for Exam
Success
1. A patient with atrial fibrillation is initiated on apixaban. Which of the following best describes
the primary pharmacokinetic parameter that necessitates dose adjustment in patients with severe
renal impairment?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Clearance
Answer: D
Rationale: Apixaban is primarily eliminated via renal excretion (approximately 27%) and metabolism. In
severe renal impairment, clearance decreases significantly, leading to increased exposure. Dose
adjustment is recommended for patients with CrCl <15 mL/min or on dialysis. Half-life is affected but
clearance is the primary parameter governing dosing adjustments.
2. A patient with type 2 diabetes and established cardiovascular disease is being started on a
GLP-1 receptor agonist. Which of the following agents has the strongest evidence for reducing
major adverse cardiovascular events (MACE) according to recent CVOTs?
A. Dulaglutide
B. Liraglutide
C. Semaglutide (injectable)
D. Exenatide
Answer: C
Rationale: In the SUSTAIN-6 trial, semaglutide (injectable) demonstrated a significant 26% reduction in
the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
While liraglutide (LEADER) and dulaglutide (REWIND) also showed benefit, semaglutide had the most
pronounced effect on MACE reduction among these agents. Exenatide has not shown significant CV
benefit.
3. In the setting of an acute ischemic stroke, alteplase is administered within 3 hours of symptom
onset. Which of the following best describes the mechanism by which alteplase exerts its
therapeutic effect?
A. Direct inhibition of platelet aggregation via P2Y12 receptor antagonism
B. Activation of plasminogen to plasmin, leading to fibrinolysis
C. Inhibition of thrombin via antithrombin III
D. Blockade of vitamin K-dependent clotting factors
Page 1
,Answer: B
Rationale: Alteplase is a recombinant tissue plasminogen activator (tPA) that binds to fibrin in a clot and
converts plasminogen to plasmin, which degrades fibrin and dissolves the thrombus. Options A, C, and
D describe mechanisms of antiplatelet agents, heparin, and warfarin respectively, not thrombolytics.
4. A patient receiving vancomycin for a MRSA bloodstream infection has a trough level of 8.5
mcg/mL. The MIC of the isolate is 1 mcg/mL. Which of the following is the most appropriate
adjustment to achieve a target AUC/MIC ratio of 400-600?
A. Increase dose, maintain same interval
B. Decrease dose, maintain same interval
C. Increase interval, maintain same dose
D. No change needed
Answer: A
Rationale: A trough of 8.5 mcg/mL with MIC 1 suggests an AUC/MIC below 400 (target 400-600). To
increase AUC, a higher dose is needed. Increasing the interval (option C) would lower the trough
further. Option D is incorrect as current exposure is subtherapeutic. Option B would worsen the
situation.
5. Which of the following vaccines is contraindicated in a patient with a history of anaphylaxis to
neomycin?
A. Influenza (inactivated)
B. Measles, mumps, rubella (MMR)
C. Hepatitis B
D. Pneumococcal conjugate (PCV13)
Answer: B
Rationale: MMR and varicella vaccines contain neomycin as a stabilizer. Anaphylaxis to neomycin is a
contraindication to these vaccines. Inactivated influenza, hepatitis B, and PCV13 do not contain
neomycin. Option A, C, and D are safe to administer.
6. A patient is prescribed a medication that is a substrate of CYP3A4 and has a narrow therapeutic
index. Which of the following concomitant medications would most likely require a dose reduction
of the substrate?
A. Phenytoin
B. Carbamazepine
C. Clarithromycin
D. St. John's wort
Answer: C
Rationale: Clarithromycin is a strong CYP3A4 inhibitor, which would decrease metabolism of the
substrate, increasing its levels and risk of toxicity. Phenytoin, carbamazepine, and St. John's wort are
inducers of CYP3A4, which would reduce substrate levels, potentially requiring a dose increase.
Page 2
,7. A patient with a history of severe asthma and GERD is started on a beta-blocker for heart
failure. Which beta-blocker is most appropriate in this patient?
A. Propranolol
B. Metoprolol tartrate
C. Carvedilol
D. Bisoprolol
Answer: D
Rationale: Bisoprolol is a cardioselective beta-1 blocker with the highest beta-1 selectivity among the
options, minimizing risk of bronchospasm in patients with asthma. Propranolol is nonselective and
contraindicated. Metoprolol tartrate and carvedilol have lower selectivity or additional alpha-blockade
(carvedilol) which may worsen asthma.
8. A patient on long-term phenytoin therapy develops nystagmus, ataxia, and slurred speech.
Serum phenytoin level is 35 mcg/mL. Which of the following best explains the altered
pharmacokinetics leading to toxicity?
A. Saturable metabolism due to Michaelis-Menten kinetics
B. Decreased protein binding leading to increased free fraction
C. Increased volume of distribution due to tissue accumulation
D. Renal impairment reducing clearance
Answer: A
Rationale: Phenytoin exhibits nonlinear (Michaelis-Menten) pharmacokinetics; at high concentrations,
metabolic pathways become saturated, leading to disproportionate increases in serum levels with small
dose increases. This is the classic cause of phenytoin toxicity. While protein binding changes can occur,
the primary mechanism is saturable metabolism.
9. A patient with a history of opioid use disorder is being considered for medication-assisted
treatment. Which of the following is a full mu-opioid receptor agonist and is only available through
specialized prescribers under the Drug Addiction Treatment Act?
A. Buprenorphine
B. Methadone
C. Naltrexone
D. Naloxone
Answer: B
Rationale: Methadone is a full mu-opioid agonist used for opioid use disorder, and its prescription is
restricted to opioid treatment programs (OTPs) certified by SAMHSA, not via the DATA 2000 waiver.
Buprenorphine is a partial agonist and can be prescribed by waivered providers. Naltrexone is an
antagonist, and naloxone is used for reversal.
10. A patient is receiving a parenteral nutrition solution through a central line. Which of the
following additives requires the use of a 1.2-micron filter to prevent infusion of precipitates?
A. Potassium chloride
B. Calcium gluconate
Page 3
, C. Magnesium sulfate
D. Fat emulsion
Answer: B
Rationale: Calcium gluconate can form insoluble calcium phosphate precipitates in parenteral nutrition
solutions, especially when combined with phosphate. A 1.2-micron filter is used to trap these
precipitates. Fat emulsions require a 1.2-micron filter to remove large lipid globules, but the question
specifies additives; calcium is the most concerning for precipitation. Potassium and magnesium are
generally stable.
11. A patient with a history of recurrent Clostridioides difficile infection (rCDI) has failed two
standard courses of oral vancomycin. They are now being considered for fecal microbiota
transplantation (FMT). According to the latest IDSA guidelines, which of the following is the most
appropriate next step in management?
A. Repeat a 14-day course of oral vancomycin with a prolonged taper
B. Administer intravenous metronidazole
C. Proceed with FMT after obtaining informed consent and screening donor stool for multidrug-resistant
organisms
D. Switch to fidaxomicin 200 mg twice daily for 10 days
Answer: D
Rationale: For patients with rCDI who have failed two courses of standard therapy (vancomycin or
fidaxomicin), the IDSA recommends a course of fidaxomicin (200 mg twice daily for 10 days) as the
preferred next step. FMT is reserved for patients who fail this approach. Repeating vancomycin taper is
an option but not the most appropriate after two failures. Metronidazole is not recommended for rCDI
due to inferior efficacy.
12. A patient with EGFR-mutant non-small cell lung cancer (NSCLC) develops progressive disease
after 12 months on osimertinib. A repeat biopsy reveals a MET amplification. Which of the
following targeted therapy combinations is most appropriate?
A. Switch to erlotinib plus bevacizumab
B. Add crizotinib to osimertinib
C. Discontinue osimertinib and start nivolumab plus ipilimumab
D. Continue osimertinib and add a MEK inhibitor
Answer: B
Rationale: MET amplification is a common resistance mechanism to osimertinib. The addition of a MET
inhibitor, such as crizotinib, to ongoing osimertinib is a guideline-recommended strategy. Erlotinib is
not effective after osimertinib failure. Immunotherapy is not targeted for MET amplification. MEK
inhibitors are not indicated for MET-driven resistance.
13. A patient on warfarin for mechanical mitral valve has an INR of 5.8 without bleeding.
According to the 2023 ACC/AHA guidelines, what is the most appropriate management?
A. Hold warfarin, give 5 mg oral phytonadione, and recheck INR in 24 hours
B. Hold warfarin, give 2.5 mg oral phytonadione, and recheck INR in 48 hours
C. Hold warfarin, give 1 mg IV phytonadione, and recheck INR in 12 hours
Page 4
Study Guide with 100% Verified Answers for Exam
Success
1. A patient with atrial fibrillation is initiated on apixaban. Which of the following best describes
the primary pharmacokinetic parameter that necessitates dose adjustment in patients with severe
renal impairment?
A. Volume of distribution
B. Bioavailability
C. Half-life
D. Clearance
Answer: D
Rationale: Apixaban is primarily eliminated via renal excretion (approximately 27%) and metabolism. In
severe renal impairment, clearance decreases significantly, leading to increased exposure. Dose
adjustment is recommended for patients with CrCl <15 mL/min or on dialysis. Half-life is affected but
clearance is the primary parameter governing dosing adjustments.
2. A patient with type 2 diabetes and established cardiovascular disease is being started on a
GLP-1 receptor agonist. Which of the following agents has the strongest evidence for reducing
major adverse cardiovascular events (MACE) according to recent CVOTs?
A. Dulaglutide
B. Liraglutide
C. Semaglutide (injectable)
D. Exenatide
Answer: C
Rationale: In the SUSTAIN-6 trial, semaglutide (injectable) demonstrated a significant 26% reduction in
the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
While liraglutide (LEADER) and dulaglutide (REWIND) also showed benefit, semaglutide had the most
pronounced effect on MACE reduction among these agents. Exenatide has not shown significant CV
benefit.
3. In the setting of an acute ischemic stroke, alteplase is administered within 3 hours of symptom
onset. Which of the following best describes the mechanism by which alteplase exerts its
therapeutic effect?
A. Direct inhibition of platelet aggregation via P2Y12 receptor antagonism
B. Activation of plasminogen to plasmin, leading to fibrinolysis
C. Inhibition of thrombin via antithrombin III
D. Blockade of vitamin K-dependent clotting factors
Page 1
,Answer: B
Rationale: Alteplase is a recombinant tissue plasminogen activator (tPA) that binds to fibrin in a clot and
converts plasminogen to plasmin, which degrades fibrin and dissolves the thrombus. Options A, C, and
D describe mechanisms of antiplatelet agents, heparin, and warfarin respectively, not thrombolytics.
4. A patient receiving vancomycin for a MRSA bloodstream infection has a trough level of 8.5
mcg/mL. The MIC of the isolate is 1 mcg/mL. Which of the following is the most appropriate
adjustment to achieve a target AUC/MIC ratio of 400-600?
A. Increase dose, maintain same interval
B. Decrease dose, maintain same interval
C. Increase interval, maintain same dose
D. No change needed
Answer: A
Rationale: A trough of 8.5 mcg/mL with MIC 1 suggests an AUC/MIC below 400 (target 400-600). To
increase AUC, a higher dose is needed. Increasing the interval (option C) would lower the trough
further. Option D is incorrect as current exposure is subtherapeutic. Option B would worsen the
situation.
5. Which of the following vaccines is contraindicated in a patient with a history of anaphylaxis to
neomycin?
A. Influenza (inactivated)
B. Measles, mumps, rubella (MMR)
C. Hepatitis B
D. Pneumococcal conjugate (PCV13)
Answer: B
Rationale: MMR and varicella vaccines contain neomycin as a stabilizer. Anaphylaxis to neomycin is a
contraindication to these vaccines. Inactivated influenza, hepatitis B, and PCV13 do not contain
neomycin. Option A, C, and D are safe to administer.
6. A patient is prescribed a medication that is a substrate of CYP3A4 and has a narrow therapeutic
index. Which of the following concomitant medications would most likely require a dose reduction
of the substrate?
A. Phenytoin
B. Carbamazepine
C. Clarithromycin
D. St. John's wort
Answer: C
Rationale: Clarithromycin is a strong CYP3A4 inhibitor, which would decrease metabolism of the
substrate, increasing its levels and risk of toxicity. Phenytoin, carbamazepine, and St. John's wort are
inducers of CYP3A4, which would reduce substrate levels, potentially requiring a dose increase.
Page 2
,7. A patient with a history of severe asthma and GERD is started on a beta-blocker for heart
failure. Which beta-blocker is most appropriate in this patient?
A. Propranolol
B. Metoprolol tartrate
C. Carvedilol
D. Bisoprolol
Answer: D
Rationale: Bisoprolol is a cardioselective beta-1 blocker with the highest beta-1 selectivity among the
options, minimizing risk of bronchospasm in patients with asthma. Propranolol is nonselective and
contraindicated. Metoprolol tartrate and carvedilol have lower selectivity or additional alpha-blockade
(carvedilol) which may worsen asthma.
8. A patient on long-term phenytoin therapy develops nystagmus, ataxia, and slurred speech.
Serum phenytoin level is 35 mcg/mL. Which of the following best explains the altered
pharmacokinetics leading to toxicity?
A. Saturable metabolism due to Michaelis-Menten kinetics
B. Decreased protein binding leading to increased free fraction
C. Increased volume of distribution due to tissue accumulation
D. Renal impairment reducing clearance
Answer: A
Rationale: Phenytoin exhibits nonlinear (Michaelis-Menten) pharmacokinetics; at high concentrations,
metabolic pathways become saturated, leading to disproportionate increases in serum levels with small
dose increases. This is the classic cause of phenytoin toxicity. While protein binding changes can occur,
the primary mechanism is saturable metabolism.
9. A patient with a history of opioid use disorder is being considered for medication-assisted
treatment. Which of the following is a full mu-opioid receptor agonist and is only available through
specialized prescribers under the Drug Addiction Treatment Act?
A. Buprenorphine
B. Methadone
C. Naltrexone
D. Naloxone
Answer: B
Rationale: Methadone is a full mu-opioid agonist used for opioid use disorder, and its prescription is
restricted to opioid treatment programs (OTPs) certified by SAMHSA, not via the DATA 2000 waiver.
Buprenorphine is a partial agonist and can be prescribed by waivered providers. Naltrexone is an
antagonist, and naloxone is used for reversal.
10. A patient is receiving a parenteral nutrition solution through a central line. Which of the
following additives requires the use of a 1.2-micron filter to prevent infusion of precipitates?
A. Potassium chloride
B. Calcium gluconate
Page 3
, C. Magnesium sulfate
D. Fat emulsion
Answer: B
Rationale: Calcium gluconate can form insoluble calcium phosphate precipitates in parenteral nutrition
solutions, especially when combined with phosphate. A 1.2-micron filter is used to trap these
precipitates. Fat emulsions require a 1.2-micron filter to remove large lipid globules, but the question
specifies additives; calcium is the most concerning for precipitation. Potassium and magnesium are
generally stable.
11. A patient with a history of recurrent Clostridioides difficile infection (rCDI) has failed two
standard courses of oral vancomycin. They are now being considered for fecal microbiota
transplantation (FMT). According to the latest IDSA guidelines, which of the following is the most
appropriate next step in management?
A. Repeat a 14-day course of oral vancomycin with a prolonged taper
B. Administer intravenous metronidazole
C. Proceed with FMT after obtaining informed consent and screening donor stool for multidrug-resistant
organisms
D. Switch to fidaxomicin 200 mg twice daily for 10 days
Answer: D
Rationale: For patients with rCDI who have failed two courses of standard therapy (vancomycin or
fidaxomicin), the IDSA recommends a course of fidaxomicin (200 mg twice daily for 10 days) as the
preferred next step. FMT is reserved for patients who fail this approach. Repeating vancomycin taper is
an option but not the most appropriate after two failures. Metronidazole is not recommended for rCDI
due to inferior efficacy.
12. A patient with EGFR-mutant non-small cell lung cancer (NSCLC) develops progressive disease
after 12 months on osimertinib. A repeat biopsy reveals a MET amplification. Which of the
following targeted therapy combinations is most appropriate?
A. Switch to erlotinib plus bevacizumab
B. Add crizotinib to osimertinib
C. Discontinue osimertinib and start nivolumab plus ipilimumab
D. Continue osimertinib and add a MEK inhibitor
Answer: B
Rationale: MET amplification is a common resistance mechanism to osimertinib. The addition of a MET
inhibitor, such as crizotinib, to ongoing osimertinib is a guideline-recommended strategy. Erlotinib is
not effective after osimertinib failure. Immunotherapy is not targeted for MET amplification. MEK
inhibitors are not indicated for MET-driven resistance.
13. A patient on warfarin for mechanical mitral valve has an INR of 5.8 without bleeding.
According to the 2023 ACC/AHA guidelines, what is the most appropriate management?
A. Hold warfarin, give 5 mg oral phytonadione, and recheck INR in 24 hours
B. Hold warfarin, give 2.5 mg oral phytonadione, and recheck INR in 48 hours
C. Hold warfarin, give 1 mg IV phytonadione, and recheck INR in 12 hours
Page 4
